Hematology lab
Home Labs Central Lab Therapeutic Expertise Hematology & Oncology

Hematology & Oncology
Laboratory Services

Hematology & Oncology Laboratory Experience

Along with our experienced CRO and strategic anatomical pathology lab partners, Medpace’s central lab has broad experience in managing oncology (e.g. Hematological, Immuno-Therapy, and Solid Tumors) clinical trials. Medpace has been proactive in implementing testing capabilities that match the spectrum of oncology clinical development approaches needed to support pharmaceutical industry partners.

Medpace’s central lab has a team of PhD directors overseeing the expansion of Medpace’s oncology test menu with newly validated biomarkers in support of our clients’ oncology programs. Medpace’s oncology capabilities include histology, flow cytometry, molecular/genomics (e.g. PCR, NGS and Sanger Sequencing), as well as many oncology biomarkers.

Central Lab Services

  • Alpha Fetoprotein
  • Autotaxin
  • Bioinformatics
  • CA125
  • Carcinoembryonic Antigen
  • CK-18 M30 Apoptosense
  • CK-18 M65 EpiDeath
  • C-Met
  • Companion Diagnostics
  • DNA Extraction (Concentration, Purity, Yield)
  • Fecal Occult Blood
  • Fibroblast Growth Factors (2, 21, 23)
  • Mesothelin
  • MIA (CD-RAP)
  • Midkine
  • Neuron Specific Enolase
  • Next Generation Sequencing
  • PBMC Processing
  • PCR/qPCR
  • Prostate-Specific Antigen
  • RNA Extraction (Concentration, Purity, Yield)
  • S-100
  • Sanger Sequencing
  • Vascular Adhesion Molecule (VCAM-1)
  • Vascular Endothelial Growth Factor (VEGF)
  • VEGF-A
  • VEGF-R2
Histology Lab Tissue Processing
Lab Talk: Histology & Anatomic Pathology

Histology & Anatomic Pathology Services

Medpace’s histology services complement the central lab’s continually expanding molecular and flow cytometry capabilities to help Medpace manage oncology clinical trials. We have been proactive in implementing testing capabilities that match the spectrum of oncology clinical development approaches needed to support pharmaceutical industry partners.

  • H&E staining
  • Special stains (e.g. Trichrome, Reticulin)
  • IHC (e.g. PD-L1 SP263, PD-L1 22C3, HER2, ER, PgR)
  • ISH (e.g. HER2)
  • Whole slide digital imaging capability
  • LDT assays for exploratory biomarker development/research
  • Macrodissection capability intended for downstream molecular assays
  • Central pathology review by board-certified pathologists with subspecialty expertise